Roche's Drug Candidate Meets Main Goals in Late-Stage Breast Cancer Study The pharmaceutical company said that giredestrant in combination with everolimus significantly improved progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback